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MaBACKGROUND Although obesity is an independent risk factor for heart failure (HF), once HF is established, obesity is
associated with lower mortality. It is unclear if the weight loss due to advanced HF leads to this paradoxical ﬁnding.
OBJECTIVES This study sought to evaluate the prognostic impact of pre-morbid obesity in patients with HF.
METHODS In the ARIC (Atherosclerosis Risk In Communities) study, we used body mass index (BMI) measured
$6 months before incident HF (pre-morbid BMI) to evaluate the association of overweight (BMI 25 to <30 kg/m2)
and obesity (BMI $30 kg/m2) compared with normal BMI (18.5 to <25 kg/m2) with mortality after incident HF.
RESULTS Among 1,487 patients with incident HF, 35% were overweight and 47% were obese by pre-morbid BMI
measured 4.3  3.1 years before HF diagnosis. Over 10-year follow-up after incident HF, 43% of patients died. After
adjustment for demographics and comorbidities, being pre-morbidly overweight (hazard ratio [HR]: 0.72; 95% conﬁ-
dence interval [CI]: 0.58 to 0.90; p ¼ 0.004) or obese (HR: 0.70; 95% CI: 0.56 to 0.87; p ¼ 0.001) had a protective
association with survival compared with normal BMI. The protective effect of overweight and obesity was consistent
across subgroups on the basis of a history of cancer, smoking, and diabetes.
CONCLUSIONS Our results, for the ﬁrst time, demonstrate that patients who were overweight or obese before
HF development have lower mortality after HF diagnosis compared with normal BMI patients. Thus, weight
loss due to advanced HF may not completely explain the protective effect of higher BMI in HF patients.
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ABBR EV I A T I ON S
AND ACRONYMS
BMI = body mass index
CHD = coronary heart disease
DM = diabetes mellitus
HF = heart failure
MI = myocardial infarction
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2744O besity has reached epidemic pro-portions in the United States, withmore than two-thirds of adults be-
ing either overweight or obese (1). Obesity is
linked to the development of cardiovascular
diseases including atherosclerosis and hyper-
tension (2). Although independently associ-
ated with the development of heart failure(HF) (3,4), obesity also has been shown to be associ-
ated with better survival once HF is established
(5,6–9); this is often referred to as the “obesity
paradox” (10).SEE PAGE 2750One plausible explanation for this paradox: HF
patients who gain or preserve their weight may
represent a noncatabolic subgroup of HF patients
with different neurohormonal, inﬂammatory, and
metabolic proﬁles compared with HF patients who
lose weight. The known protective effects of the
ability to maintain or gain weight in other chronic
diseases or catabolic states such as the acquired im-
munodeﬁciency syndrome, renal disease, and cancer
lend support to this concept (11). Therefore, sponta-
neous weight loss (cachexia in extreme cases) after
the development of HF may characterize a sicker
group of patients with HF and, thus, may be associ-
ated with greater mortality (12).
However, it is not clear if weight loss after devel-
opment of HF is the sole contributor to the obesity
paradox or whether additional mechanisms, such as
pre-existing obesity with possibly greater metabolic
reserve prior to HF onset, contribute to the better
survival of HF patients. Therefore, we examined the
relationship of pre-morbid obesity (i.e., prior to inci-
dent HF) with mortality following incident HF. To
our knowledge, this is the ﬁrst study to investigate
the prognostic implications of pre-morbid obesity
with outcomes after the development of HF.
METHODS
STUDY COHORT. The ARIC (Atherosclerosis Risk In
Communities) study is an ongoing, community-based
cohort study of 15,792 patients, comprised mostly of
Caucasian and African-American men and women, age
45 to 64 years at baseline (1987 to 1989), and sampled
from 4 U.S. communities: Forsyth County, North Car-
olina; suburbs ofMinneapolis, Minnesota;Washington
County, Maryland; and Jackson, Mississippi (13). The
institutional review boards from each site approved
the ARIC study, and all participants provided written
informed consent. Standardized physical examina-
tions and interviewer-administered questionnaireswere conducted at baseline (visit 1) and at approxi-
mately 3-year follow-up intervals (visit 4: 1996 to
1998). Participant follow-up through annual telephone
interviews, hospitalization, and vital status is ongoing.
Patients with missing anthropometry (n ¼ 33), with
prevalent HF at the ﬁrst study visit (n ¼ 751), and with
missing data to determine prevalent HF at baseline
(n¼ 289) were excluded (14). Participantswith race not
classiﬁed as white or black (n¼ 48) and blacks not from
Jackson or Forsyth County (n¼ 120) were excluded due
to their limited numbers.
ASCERTAINMENT OF HF CASES AND FOLLOW-UP.
To determine HF cases, the following methods were
used: 1) annual interviews of participants regarding
interim hospitalizations (response rate: 93% to 96%);
2) review of discharge lists from local hospitals;
and 3) survey of health department death certiﬁcate
ﬁles and the national death index. Incident HF was
deﬁned as the ﬁrst episode of either a hospitaliza-
tion that included an International Classiﬁcation of
Diseases-9th Revision (ICD-9)-Clinical Modiﬁcation
discharge diagnosis code for HF beginning with “428”
(i.e., 428.0 to 428.9) in any position, a death certiﬁ-
cate ICD-9 code beginning with “428,” or ICD-10 code
“I50” (HF or I50.0 to I50.9) in any position. For this
study, incident HF was determined until December
31, 2004; date of last contact; or death (14).
ANTHROPOMETRY. Participants presented for each
study visit after an overnight fast, and measurements
were taken in standard scrub attire. Weight was
measured using a scale that was zeroed daily and
calibrated quarterly. Pre-morbid body mass index
(BMI) was deﬁned as a BMI measurement from a
study visit that occurred 6 months or more prior to
the incident date of HF. Patients with HF were cate-
gorized by the pre-morbid BMI into normal (18.5
to <25 kg/m2), overweight (25 to <30 kg/m2), and
obese ($30 kg/m2) groups (15). Patients in the un-
derweight category (BMI <18.5 kg/m2; n ¼ 32) were
excluded from this analysis because of small numbers
and possible other pre-existing comorbidities that
may have led to a cachectic state.
BASELINE COVARIATES. Ascertainment of de-
mographics and comorbidities at each study visit has
been described in detail previously (13). Age was
assessed at the time of incident HF, and sex, race, and
education level were obtained from the baseline ARIC
visit with interviewer-administered questionnaires.
Comorbidities, including hypertension, history of
myocardial infarction (MI), coronary heart disease
(CHD), diabetes mellitus (DM), and stroke, were
assessed as present if these conditions were docu-
mented at any of the pre-HF study visits. History of
TABLE 1 Baseline Characteristics in Patients With Incident HF
Normal Weight
(n ¼ 274)
Overweight
(n ¼ 518)
Obese
(n ¼ 695) p Value
Age at incident HF, yrs 67  6 67  7 66  7 0.02
Male 149 (54) 338 (65) 316 (45) <0.0001
Black 73 (27) 155 (30) 279 (40) 0.0001
Education level 0.02
Did not graduate HS 101 (37) 198 (38) 303 (44)
HS graduate 105 (38) 173 (33) 248 (36)
Higher than HS 67 (25) 146 (28) 143 (21)
Health insurance 232 (85) 423 (82) 541 (78) 0.03
Diabetes mellitus 58 (21) 185 (36) 359 (52) <0.0001
Hypertension 168 (61) 358 (69) 537 (77) <0.0001
History of MI (by history or ECG) 56 (20) 123 (24) 159 (23) 0.57
History of CAD 55 (20) 127 (25) 143 (21) 0.19
History of stroke 17 (6) 44 (8) 47 (7) 0.39
History of cancer 41 (15) 68 (13) 79 (11) 0.29
Current smoker 129 (47) 162 (32) 149 (22) <0.0001
History of alcohol use 117 (43) 225 (44) 227 (33) 0.0004
Total serum cholesterol, mg/dl 204  42 207  46 210  46 0.27
Blood pressure, mm Hg
Systolic 137  26 138  25 141  24 0.01
Diastolic 71  13 72  13 73  13 0.08
Estimated GFR, ml/min/1.73 m2 85  26 82  23 83  25 0.14
Time to HF, yrs* 4.2  3.2 4.2  3.1 4.4  3.2 0.49
Values are mean  SD or n (%). *Time to HF ¼ time between the pre-HF ARIC study visit and
incident HF hospitalization.
ARIC ¼ Atherosclerosis Risk In Communities; CAD ¼ coronary artery disease; ECG ¼ electro-
cardiogram; GFR ¼ glomerular ﬁltration rate; HF ¼ heart failure; HS ¼ high school;
MI ¼ myocardial infarction.
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MI or electrocardiographic diagnosis of silent MI.
CHD was deﬁned as history of MI, coronary revascu-
larization, or coronary artery bypass surgery. Hyper-
tension was deﬁned by either: 1) a systolic blood
pressure (SBP) $140 mm Hg or diastolic blood
pressure $90 mm Hg measured with random-zero
mercury manometers; or 2) recent antihypertensive
medication use. Presence of DM was deﬁned as either
self-reported physician-diagnosed diabetes, recent
diabetes medication use, or a blood glucose $126
mg/dl fasting or $200 mg/dl nonfasting (13).
Alcohol use, SBP, serum creatinine, total serum
cholesterol, and insurance status also were collected
from the pre-HF ARIC study visit. Patients were
deﬁned as smokers if the participants reported a his-
tory of current smoking at the pre-HF ARIC study visit.
A history of cancer reported at any study visit prior to
or including the pre-HF visit was used to deﬁne a
positive history of cancer. Data for any variables with
missing values at the pre-HF visit utilized available
data from prior study visits. Renal function was quan-
tiﬁed by the estimated glomerular ﬁltration rate using
the Modiﬁcation of Diet in Renal Disease equation (16).
STATISTICAL ANALYSIS. Data are shown as mean 
SD and percents. Missing values were found to
be <0.8%. Univariate differences among the 3 BMI
groups were examined using the chi-square test for
categorical variables and the analysis of variance test
for continuous variables. To assess the prognostic
signiﬁcance of pre-morbid BMI in HF patients, the
endpoint was time to all-cause mortality after incident
HF. We performed Kaplan-Meier survival analysis and
used the log-rank test to compare time to death after
incident HF among the 3 BMI groups. Because the
number of patients after 10-year follow-up from the
incident HF episode was small, we censored the
follow-up after incident HF at 10 years. Cox propor-
tional hazard models were used to examine the rela-
tionship between the BMI group and survival. Due to
violation of the proportionality assumption, a time-
dependent term, the product of BMI group and log
time was added to the model to represent the non-
homogeneity of the hazard (17). The adjusted model
was ﬁtted by adding age, sex, race, history of MI, hy-
pertension, CHD, DM, stroke, cancer, alcohol use,
smoking status, insurance, education level, SBP, and
estimated glomerular ﬁltration rate as covariates. Due
to concerns related to smoking and history of cancer
and their association with BMI status and mortality, as
well as the fact that statistical adjustments may not be
sufﬁcient to control for duration, intensity, or timing
of smoking exposure, we also conducted subgroup
analyses by the presence or absence of a history ofsmoking and cancer. Similarly, due to prior studies
demonstrating a possible differential effect of obesity
and overweight on mortality in HF patients on the
basis of diabetic status, we also performed subgroup
analysis by the presence or absence of DM (5,7,18–22).
All p values <0.05 were considered to be signiﬁcant.
All analyses were performed using SAS version 9.3
(SAS Institute Inc., Cary, North Carolina).
RESULTS
The study cohort consisted of 1.487 HF patients
categorized as normal, overweight, or obese on the
basis of BMI obtained at least 6 months before inci-
dent HF. Overall, 54% of the HF patients were male
and 66% were white; they averaged 67 years of age at
the time of diagnosis. Pre-morbidly, the majority of
patients were either overweight (35%) or obese (47%).
The pre-morbid BMI was measured 4.3  3.1 years
before the HF diagnosis at the last ARIC study visit,
which occurred at least 6 months before incident HF.
Baseline characteristics of patients with incident HF
by the 3 pre-morbid BMI groups are shown in Table 1.
Compared with HF patients with normal BMI, obese
HF patients were younger, were more often African
TABLE 2 Hazard Ratios for All-Cause Mortality After Incident HF
BMI Category
Incident
HF
Deaths Over
10 Years
Adjusted Hazard Ratio
(95% CI)* p Value†
Normal 274 141 (51) 1.00
Overweight 519 232 (45) 0.72 (0.58–0.90) 0.99
Obese 695 265 (38) 0.70 (0.56–0.87) 0.02
Values are n or n (%). *The models included the following covariates in addition to
BMI and time-dependent term of group*log (time in years): age; sex; race; edu-
cation level; health insurance; diabetes; hypertension; history of MI, CAD, or
stroke; cancer; smoking; alcohol use; systolic blood pressure; total cholesterol;
and estimated GFR. †For BMI group*log time interaction.
BMI ¼ body mass index; CI ¼ conﬁdence interval; other abbreviations as in
Table 1.
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2746American, were less likely to have health insurance,
and attained a lower education level. Overweight and
obese HF patients had higher prevalence of comor-
bidities such as DM and hypertension, as well as
higher SBP. Smoking was associated with lower BMI.
There was no signiﬁcant difference in the time period
of measurement of BMI before incident HF among
the 3 BMI categories.
Over a follow-up period of 10 years, a total of 43%
of all HF patients died. The Central Illustration shows
the Kaplan-Meier survival curves by BMI group over
10-year follow-up after incident HF. The overweight
and obese groups had better survival compared with
the normal-weight group. Over time, the survival
curve for the obese patients appeared to converge
toward the other groups, and crossed over the over-
weight group at w7.5 years of follow-up. However,
the curves for overweight patients appeared to re-
main parallel to the normal-weight group. Compared
with normal BMI, overweight (hazard ratio [HR]: 0.77;
95% conﬁdence interval [CI]: 0.62 to 0.96) and
obesity (HR: 0.75; 95% CI: 0.61 to 0.91) were associ-
ated with improved survival. As expected from the
Kaplan-Meier curves, the interaction between the
BMI group and log time was not signiﬁcant for the
overweight group (p ¼ 0.74), but was signiﬁcant for
the obese group (p ¼ 0.02). The interaction terms
were, therefore, included in the models. As shown
in Table 2, even after adjusting for covariates,
pre-morbid overweight and obesity remained inde-
pendent predictors of improved survival compared
with normal BMI.TRATION Kaplan-Meier Survival Curves in HF Patients
ategories
velopment of heart failure (HF) differed signiﬁcantly among body
oups deﬁned by pre-HF BMI. The overweight and obese patients had
ared with the normal-weight group.A sensitivity analysis was performed after
excluding patients with a presentation of fatal inci-
dent HF. Again, the overweight (adjusted HR: 0.72;
95% CI: 0.57 to 0.90; interaction with log time
p ¼ 0.37) and obese (adjusted HR: 0.69; 95% CI: 0.56
to 0.86; interaction with log time p < 0.001) HF
patients had signiﬁcantly better survival compared
with HF patients with normal BMI.
Subgroup analyses were conducted in HF patients
on the basis of smoking, history of cancer, and the
presence or absence of diabetes (Figure 1). The bene-
ﬁcial trends associated with pre-morbid overweight
and obesity compared with normal weight, similar to
those observed in the overall cohort, were noted in all
subgroups, although not all differences reached sta-
tistical signiﬁcance.
DISCUSSION
This study demonstrates that the majority of patients
who develop HF in the community are pre-morbidly
overweight or obese. Additionally, for the ﬁrst time,
we have shown that patients who are overweight or
obese before incident HF have better survival after
they develop HF compared with patients with normal
BMI. This association is independent of the patients’
demographic proﬁle and comorbidities. Furthermore,
this trend occurred irrespective of smoking status,
history of cancer, or diabetes.
Our ﬁndings of an association between a higher
pre-morbid BMI and improved survival following
incident HF could suggest that obese patients have a
higher metabolic reserve compared with normal-
weight patients, providing them with a survival
advantage when cardiac cachexia ensues after HF
development. Several studies have demonstrated an
obesity paradox in patients with chronic and acute
decompensated HF (i.e., a survival advantage of
higher BMI measured in patients with established HF)
FIGURE 1 Adjusted Risk of Mortality Associated
With BMI Category
Overall
(n = 1,406)
Smokers
(n = 437)
Non-smokers
(n = 1,026)
Cancer
(n = 186)
Non-cancer
(n = 1,277)
Diabetes
(n = 586)
Non-Diabetes
(n = 877)
0.1 0.5 1 2 10
Adjusted HR (95% CI)
Overweight
Obese
The adjusted hazard ratios (HRs) and 95% conﬁdence intervals
(CIs) for mortality risk for the obese and overweight groups
compared with the normal-weight group (reference group; HR:
1.00) are shown on a logarithmic scale for the overall cohort and
for the subgroups stratiﬁed by smoking, cancer, and diabetes.
The results are consistent across all subgroups.
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2747(5,7–9,18–22). It must be noted that none of the pre-
vious studies demonstrating the obesity paradox in
HF used the BMI (or BMI-equivalent variable) prior to
development of HF. Moreover, very few studies had
a follow-up >5 years (23,24). Because prior studies
used the BMI of patients with established HF, they
were unable to determine the effect of weight loss
between the time of development of HF and the BMI
measurement as a marker of more advanced HF
versus the possible survival advantage of pre-existing
obesity or overweight. Our study goes a major step
further than prior studies by demonstrating that
higher pre-morbid BMI is independently associated
with a long-term survival advantage over a long
(10-year) follow-up period.
Several proposed mechanisms could contribute to
this apparent obesity paradox, including the fact that
HF is a catabolic state leading to cachexia, and obeseand overweight patients may have better outcomes
as they have higher metabolic reserves (12,25).
Another hypothesis is that obesity alters the natural
history of HF through neurohumoral pathways. Higher
levels of serum lipoproteins may neutralize bacterial
lipopolysaccharides and thus attenuate the detri-
mental cytokine response in HF (26–29). Adipose
tissue may produce higher levels of soluble tumor
necrosis factor (TNF) receptors that serve as a re-
servoir for harmful circulating TNF (30). Levels
of circulating stem cells are also higher in obese pa-
tients (31). Furthermore, obese patients have
decreased adiponectin levels and an attenuated renin-
angiotensin system and catecholamine response, both
of which are associated with improved HF survival
(26,32).
Another possible explanation is that obese or
overweight patients may present with and be diag-
nosed with HF at an earlier stage due to symptoms
exacerbated by excess body weight, such as dyspnea
and edema (i.e., the obesity paradox may represent
a lead-time bias). Furthermore, obese patients have
a higher prevalence of comorbidities such as hyper-
tension and DM, as supported by our study, and may
represent a higher-risk population for HF. Another
possibility is that the higher prevalence of hyper-
tension, as well as higher blood pressures, in the
overweight and obese patients may allow for greater
up-titration of disease-modifying HF therapies. It
is interesting to note that the protective effect
of obesity was greatest during the initial years
(Central Illustration), with signiﬁcant interaction
between BMI group and time, suggesting perhaps
that during the later years, the complications of
obesity-associated comorbidities catch up and lead to
a greater decline in survival. This ﬁnding would also
be expected if a lead-time bias is contributing with an
earlier presentation with HF due to obesity-enhanced
symptoms. Unlike our analysis, most studies that
have examined the obesity paradox in patients with
established HF have had shorter follow-up periods,
usually <5 years. In contrast, the protective effect of
being overweight did not appear to decrease over
time. Although a history of cancer and smoking are
associated with lower BMI and higher mortality,
perhaps confounding the analyses of BMI and sur-
vival, our subgroup analyses did suggest that the
observed results were independent of smoking or
cancer status.
Previous studies that have evaluated the associa-
tion between obesity and cardiovascular outcomes
have used various indexes of obesity, including BMI,
waist circumference and waist-hip ratio, and percent
body fat (22,33). Whereas waist-hip ratio and waist
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Although higher BMI is associated with an increased
risk of developing clinical HF, patients with HF who are
overweight or obese have better survival rates than
those with normal weight. This obesity paradox also
applies to patients who were overweight or obese
before incident HF hospitalization, suggesting that the
paradox is not entirely accounted for by weight loss or
cardiac cachexia due to HF.
TRANSLATIONAL OUTLOOK: Further research is
needed to understand the mechanisms responsible for
the protective effect of pre-morbid overweight and
obesity and the effect of intentional weight loss on
clinical outcomes in patients with HF.
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2748circumference are better predictors of central
obesity, BMI reﬂects generalized obesity (34,35). On
the basis of previous analyses conducted on the
ARIC cohort (14), which had conﬁrmed that obesity
and overweight are independent risk factors for
developing HF, the degree and pattern of relation-
ships for the development of HF were comparable
for all 3 indexes of obesity. Also, because most pre-
vious studies that have evaluated the association
between obesity and cardiovascular outcomes have
used BMI, we used BMI as the index of obesity in
our study.
The recent HF guidelines from the American Col-
lege of Cardiology and American Heart Association do
not speciﬁcally recommend weight reduction in
obese patients with HF on the basis of the lack of
data demonstrating a beneﬁcial effect in this popu-
lation (36). Although our study suggests that patients
who are overweight/obese before the development
of HF have better survival compared with patients
of normal weight, it does not answer whether tar-
geted weight reduction in obese patients with HF is
beneﬁcial or not. Only a randomized controlled trial
of targeted weight reduction in obese patients with
HF could help resolve that question.
STUDY LIMITATIONS. Our study has inherent limita-
tions associated with an observational cohort study,
including those of possible residual confounding from
unmeasured covariates. In addition, identiﬁcation of
the cases relied on ICD-9 codes; only hospitalized
HF and incident fatal HF were included because we
lacked consistent data on outpatient HF. However,
validation of HF hospitalizations in an ARIC commu-
nity surveillance study in 2005 has shown that the
sensitivity and positive predictive value of ICD-9 code
428.x in any position for HF classiﬁed by subsequent
medical record review by ARIC criteria were 0.95
and 0.77, respectively, for combined acute decom-
pensated HF and chronic HF (in comparison to 0.83
and 0.78, respectively, by Framingham criteria) (37).
Also, the fact that there was a long time period be-
tween measurement of BMI and incident HF (mean
4.2 years) makes it unlikely that our cohort included
HF cases in whom weight loss as a result of HF would
have occurred.
Furthermore, community surveillance reports
have indicated that 74% of outpatient HF cases are
hospitalized within 1.7 years (38). Because a diag-
nosis of HF in obese patients may be less speciﬁc
than that in normal-weight patients, there is a pos-
sibility of differential misclassiﬁcation bias. Also, we
were unable to adjust for level of ﬁtness, which hasbeen shown to modify the association of BMI with
prognosis in HF (39,40). Fatal initial HF episodes
were determined from death certiﬁcates, which may
overestimate or underestimate the true number of
cases. We did not have a record of medical therapies
instituted following incident HF and were unable
to adjust for potential differences in therapy by
BMI status. Additionally, the type of HF (HF with
preserved or reduced ejection fraction) was not
known.
CONCLUSIONS
The majority of patients with incident HF in the
community have pre-existing overweight or obesity.
Once the overweight/obese patients develop HF,
they have lower mortality compared with HF pa-
tients with prior normal BMI. These results suggest
that a signiﬁcant component of the obesity paradox
is driven by pre-morbid obesity, and it is, therefore,
unlikely that cardiac cachexia due to advanced HF is
the only mechanism contributing to the observed
obesity paradox in established HF. Future studies
are needed to conﬁrm our observations in other
cohorts.
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